Robert (Bobby) Brooke obtained his MS in Biomedical Engineering from UCLA in 2005.  After graduating, Mr. Brooke worked in healthcare finance with an investment firm in Westwood before starting a career as a biotech entrepreneur.  He has founded multiple companies including an immunotherapy company now known as Iovance Biotherapeutics, a cannabinoid drug developer named Vitality Biopharma, and most recently Intervene Immune, which is focused on the prevention or reversal of age-related immune system decline.  In 2019, Intervene Immune published clinical trial results with UCLA and Stanford collaborators demonstrating reversal of immunosenescent trends, and also the first ever reversal of epigenetic aging, which is the most accurate measure of biological age available today.